Anti-proliferative effects of Chinese herb Cornus officinalis in a cell culture model for estrogen receptor-positive clinical breast cancer

Molecular Medicine Reports

Volumn 5, Issue 1, 2012, Pages 22-28

  Telang, Nitin T ^a   Li, G ^b   Sepkovic, D W ^c   Bradlow, H L ^c   Wong, G Y C ^b,d  

^a Cancer Prevention Research Program   (United States)

^b American Foundation for Chinese Medicine   (United States)

^c David and Alice Jurist Institute for Research   (United States)

^d BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Breast carcinoma; Chinese herb; Estradiol metabolism

Indexed keywords

16ALPHA HYDROXYESTRONE; 2 HYDROXYESTRONE; CORNUS OFFICINALIS EXTRACT; ESTRADIOL; ESTROGEN RECEPTOR; ESTRONE; TAMOXIFEN;

ANCHORAGE INDEPENDENT GROWTH; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER INHIBITION; CANCER THERAPY; CARCINOGENIC ACTIVITY; CELL METABOLISM; CELL STRAIN MCF 7; CHINESE HERB; COLONY FORMATION; CONTROLLED STUDY; CORNUS OFFICINALIS; CYTOSTASIS; DOSE RESPONSE; DRUG EFFICACY; FRUIT; HORMONE METABOLISM; HORMONE RELEASE; HUMAN; HUMAN CELL; NONHUMAN; QUANTITATIVE ANALYSIS; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL AGGREGATION; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; CORNUS; DRUGS, CHINESE HERBAL; ESTRADIOL; FEMALE; FRUIT; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; HYDROXYESTRONES; MODELS, BIOLOGICAL; PLANT EXTRACTS; RECEPTORS, ESTROGEN;

ANIMALIA; CORNUS OFFICINALIS;

EID: 84855219544     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.617     Document Type: Article

References (38)

1. Siegel R, Ward E, Brawley O, et al: Cancer Statistics-2011. CA Cancer J Clin 61: 212-236-, 2011.
2. Lippman ME: Efforts to combine endocrine and chemotherapy in the management of breast cancer: do two and two equals three? Breast Cancer Res Treat 3: 117-127, 1983.
3. Early Breast Cancer Trialist's Group (EBCTG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 years survival: an overview of the randomized trials. Lancet 365: 1687-1717, 2005.
4. Molassiotis A, Scott JA, Kearney A, et al: Complementary and alternative use in breast cancer patients in Europe. Support Care Cancer 14: 206-267, 2006.
5. Rock E and DeMichele A: Nutritional approaches to late toxicities of adjuvant chemotherapy in breast cancer survivors. J Nutr 133: S3785-S3793, 2003.
6. Hyler LK, Chin S, Chui BK, et al: The use of complementary and alternative medicines among patients with locally advanced breast cancer . a descriptive study. BMC Cancer 6: 39-46, 2006.
7. Tindle HA, Davis RB, Phillips RL, et al: Trends in the use of complementary and alternative medicines by US adults: 1997.2002. Altern Ther Health Med 11: 42-49, 2005. (Pubitemid 40110627)
8. Cao GW, Yang WG and Du P: Observations of the effects of LAK/IL-2 therapy combining with Lycium barbarum polysaccharides in treatment of 75 cancer patients. Zhonghua Zong Liu Zha Zhi 16: 428-431, 1994 (In Chinese).
9. Gan L, Hua Zhang S, Liang Yang X and Bi Xu H: Immuno-modulation and anti-tumor activity by a polysaccharide-protein complex from Lycium barbarum. Int J Immunopharmacol 4: 563-569, 2004. (Pubitemid 38501664)
10. Zhou S-F: Chinese herbal medicines for toxicity reduction in cancer chemotherapy. Aust J Acupunct Chinese Med 2: 30-31, 2007.
11. Lippman ME, Osborne CK, Knazek R and Young N: In vitro model systems for the study of hormone-dependent human breast cancer. N Engl J Med 296: 154-159, 1977.
12. Suto A, Bradlow HL Kubota T, et al: Alteration in proliferative and endocrine responsiveness of human mammary carcinoma cells by prototypic tumor-suppressing agents. Steroids 58: 212-219, 1993.
13. Sepkovic DW, Bradlow HL, Michnovicz J, et al: Catachol estrogen production in rat microsomes after treatment with indole-3-carbinol, ascorbigen, or β-napthaflavone: a comparison of stable isotope dilution, gas chromatography-mass spectrophotometry and radiometric methods. Steroids 59: 318-323, 1994.
14. Dehenin L, Reiffsteck A and Scholler R: Simple methods for the synthesis of twenty different highly enriched deuterium labeled steroids suitable as internal standards for isotope dilution mass spectrometry. Biochem Mass Spectrometry 7: 493-499, 1980. (Pubitemid 11157460)
15. Raju U, Sepkovic DW, Dixon JM, et al: Estrone and estradiol metabolism in vivo in human breast cysts. Steroids 65: 883-888, 2000.
16. Jordan VC: Historical perspective on hormonal therapy of advanced breast cancer. Clin Ther 24: A3-A16, 2002.
17. Suto A, Bradlow HL, Wong GY, et al: Persistent estrogen responsiveness of Ras oncogene transformed mouse mammary epithelial cells. Steroids 57: 262-268, 1992.
18. Telang NT, Narayanan R, Bradlow HL and Osborne MP: Coordinated expression of intermediate biomarkers for tumorigenic transformation of Ras transfected mouse mammary epithelial cells. Breast Cancer Res Treat 18: 155-163, 1991.
19. Telang NT, Osborne MP, Sweterlitsch LA and Narayanan R: Neoplastic transformation of mouse mammary epithelial cells by deregulated myc expression. Cell Regul 1: 863-872, 1990.
20. Telang N and Katdare M: Novel cell culture model for prevention of carcinogenic risk in familial adenomatous polyposis syndrome. Oncol Rep 21: 1017-1021, 2009.
21. Li G, Sepkovic DW, Bradlow HL, Telang NT and Wong GYC: Lycium barbarum inhibits growth of estrogen receptor-positive human breast cancer cells by favorably altering estradiol metabolism. Nutr Cancer 61: 408-414, 2009.
22. Mukherjee B, Telang NT and Wong GYC: Growth inhibition of estrogen receptor positive human breast cancer cells by Taheebo from the inner bark of Tabebuia avellande tree. Int J Mol Med 24: 253-260, 2009.
23. Schneider J, Kinne D, Frachia A, et al: Abnormal oxidative metabolism of 17β-estradiol in women with breast cancer. Proc Natl Acad Sci USA 79: 3047-3051, 1982. (Pubitemid 12058614)
24. Fishman J, Schneider J, Herschkopf RJ and Bradlow HL: Increased estrogen 16α-hydroxylase activity in women with breast and endometrial cancer. J Steroid Biochem Mol Biol 20: 1077-1081, 1984. (Pubitemid 14101045)
25. Yager JD and Davidson NE: Estrogen carcinogenesis in breast cancer. N Engl J Med 354: 270-282, 2006.
26. Castagnetta LM, Granata OM, Cocciadiferro L, et al: Sex steroids, carcinogenesis and cancer progression. Ann NY Acad Sci 1028: 233-246, 2004. (Pubitemid 40361825)
27. Fishman J, Osborne MP and Telang NT: The role of estrogens in mammary carcinogenesis. Ann NY Acad Sci 768: 91-100, 1995.
28. Telang NT: Oncogenes, estradiol metabolism and mammary carcinogenesis. Ann NY Acad Sci 784: 277-287, 1996.
29. Lottering ML, Haag M and Segers JC: Effects of 17β-estradiol metabolites on cell cycle events in MCF-7 cells. Cancer Res 52: 5926-5932, 1992.
30. Telang NT, Suto A, Wong GY, et al: Induction by estrogen metabolite 16α-hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. J Natl Cancer Inst 84: 634-638, 1992.
31. Suto A, Telang NT, Tanino H, et al: In vitro and in vivo modulation of growth regulation in the human breast cancer cell line MCF-7 by estradiol metabolites. Breast Cancer 6: 87-92, 1999.
32. Telang NT, Sepkovic DW, Bradlow HL and Wong GYC: Chinese herb Fructus Cornii exhibits preventive efficacy in a cell culture model for hormone responsive breast cancer. Cancer Res 70: S152-S153, 2010.
33. Schneider J, Huh MM, Bradlow HL and Fishman J: Anti-estrogen action of 2-hydroxyestrone on MCF-7 human breast carcinoma cells. J Biol Chem 259: 4840-4845, 1984. (Pubitemid 14144204)
34. Telang NT, Katdare M, Bradlow HL and Osborne MP: Cell cycle regulation, apoptosis and estradiol metabolism: novel end point biomarkers for human breast cancer prevention. J Clin Ligand Assays 23: 130-137, 2000.
35. Telang NT, Katdare M, Bradlow HL, et al: Inhibition of proliferation and modulation of estradiol metabolism: novel mechanisms for breast cancer prevention by the phytochemical indole-3-carbinol. Proc Soc Exp Biol Med 216: 246-252, 1997.
36. Tiwari RK, Li G, Bradlow HL, et al: Selective responsiveness of human breast cancer cells to indole-3-carbinol, a chemo-preventive agent. J Natl Cancer Inst 86: 126-131, 1994.
37. Seeram NP, Schutzki R, Chandra A, et al: Characterization, quantification and bio-activity of Anthocyanins from Cornus species. J Agri Food Chem 50: 2519-2523, 2002. (Pubitemid 34437361)
38. Chang JS, Chiang LC, Hsu FF and Lin CC: Chemoprevention against hepato-cellular carcinoma of Cornus officinalis in vitro. Am J Chinese Med 32: 717-725, 2004.